215 related articles for article (PubMed ID: 22158037)
1. Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma.
Macià A; Gallel P; Vaquero M; Gou-Fabregas M; Santacana M; Maliszewska A; Robledo M; Gardiner JR; Basson MA; Matias-Guiu X; Encinas M
Oncogene; 2012 Aug; 31(35):3961-72. PubMed ID: 22158037
[TBL] [Abstract][Full Text] [Related]
2. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract][Full Text] [Related]
3. Medullary Thyroid Carcinoma Associated with Germline RET
Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
[TBL] [Abstract][Full Text] [Related]
4. Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis.
Macià A; Vaquero M; Gou-Fàbregas M; Castelblanco E; Valdivielso JM; Anerillas C; Mauricio D; Matias-Guiu X; Ribera J; Encinas M
Cell Death Differ; 2014 Feb; 21(2):333-43. PubMed ID: 24270409
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma.
Marsh DJ; Theodosopoulos G; Martin-Schulte K; Richardson AL; Philips J; Röher HD; Delbridge L; Robinson BG
J Clin Endocrinol Metab; 2003 Apr; 88(4):1866-72. PubMed ID: 12679485
[TBL] [Abstract][Full Text] [Related]
6. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.
Koga K; Hattori Y; Komori M; Narishima R; Yamasaki M; Hakoshima M; Fukui T; Maitani Y
Cancer Sci; 2010 Apr; 101(4):941-7. PubMed ID: 20704575
[TBL] [Abstract][Full Text] [Related]
7. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
8. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
[TBL] [Abstract][Full Text] [Related]
9. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
[TBL] [Abstract][Full Text] [Related]
10. High-resolution analysis of alterations in medullary thyroid carcinoma genomes.
Flicker K; Ulz P; Höger H; Zeitlhofer P; Haas OA; Behmel A; Buchinger W; Scheuba C; Niederle B; Pfragner R; Speicher MR
Int J Cancer; 2012 Jul; 131(2):E66-73. PubMed ID: 22038905
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity.
Zhu W; Hai T; Ye L; Cote GJ
J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677
[TBL] [Abstract][Full Text] [Related]
12. Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma.
Qu N; Shi X; Zhao JJ; Guan H; Zhang TT; Wen SS; Liao T; Hu JQ; Liu WY; Wang YL; Huang S; Shi RL; Wang Y; Ji QH
Thyroid; 2020 Jul; 30(7):1025-1036. PubMed ID: 32031055
[No Abstract] [Full Text] [Related]
13. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations.
Chang TC; Wu SL; Hsiao YL
Acta Cytol; 2005; 49(5):477-82. PubMed ID: 16334022
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
15. Modifying impact of
Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R
Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230
[TBL] [Abstract][Full Text] [Related]
16. Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation.
Vantyghem MC; Pigny P; Leteurtre E; Leclerc L; Bauters C; Douillard C; D'Herbomez M; Carnaille B; Proye C; Wemeau JL; Lecomte-Houcke M
Thyroid; 2004 Oct; 14(10):842-7. PubMed ID: 15588381
[TBL] [Abstract][Full Text] [Related]
17. Current understanding and management of medullary thyroid cancer.
Roy M; Chen H; Sippel RS
Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
[TBL] [Abstract][Full Text] [Related]
18. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
20. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
